Company: IMNN
Filing Date: 2025-12-31
Form Type: 424B5
Source: 0001493152-25-029712
Chunk: 16

Company: Imunon, Inc.
Filing Date: 2025-12-31
Form: 424B5
Chunk 16
---
 common stock issuable upon exercise of the Warrants are currently traded on the Nasdaq Capital Market.

Right as a Stockholder

Except as otherwise provided in the Warrants or by virtue of such holder’s ownership of shares of our common stock, the holders of the Warrants do not have the rights or privileges of holders of our common stock, including any voting rights, until they exercise their Warrants. The Warrants will provide that holders have the right to participate in distributions or dividends paid on common stock.

| S-12 |

<div align='center'>PLAN OF DISTRIBUTION</div>

Pursuant to a placement agency agreement, dated as of December 30, 2025, we have engaged Maxim Group LLC (“Maxim”) to act as our lead Placement Agent and Brookline Capital Markets, a division of Arcadia Securities, LLC to act as a co-Placement Agent in this offering to solicit offers to purchase the securities offered by this prospectus on a reasonable best-efforts basis. The Placement Agents are not purchasing or selling any securities, nor are they required to arrange for the purchase and sale of any specific number or dollar amount of securities, other than to use their “reasonable best efforts” to arrange for the sale of the securities by us. The Placement Agents may engage one or more subagents or selected dealers in connection with this offering.

The placement agency agreement provides that each Placement Agent’s obligations are subject to the conditions contained in the placement agency agreement.

We will deliver the securities being issued to the Purchaser upon receipt of Purchaser funds for the purchase of the securities offered pursuant to this prospectus. We expect to deliver the securities being offered pursuant to this prospectus on or about December 31, 2025, subject to satisfaction of customary closing conditions. There is no minimum number of securities or amount of proceeds that is a condition to closing of this offering.

Placement Agents Fees, Commissions and Expenses

Upon the closing of this offering, we will pay the Placement Agents a cash transaction fee equal to 7.0% of the aggregate gross proceeds to us from the sale of the securities in the offering. We have agreed to reimburse the Placement Agents for their out-of-pocket accountable expenses, including the Placement Agents’ legal fees, for up to $85,000, in connection with the offering. We estimate that the total expenses of the offering, including filing and listing fees, printing fees and legal and accounting expenses, but excluding Placement Agents’ fees, will be approximately $225,000, all of which are payable by